585 articles by Delilah Alvarado

• Ferring to acquire next-gen IVF startup Gameto for up to $1.4B

  Oct. 27, 2026

• BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

  Oct. 26, 2026

• This week in charts: a big year for RNAi developers

  Oct. 23, 2026

• Biohaven’s previously rejected rare disease drug to get fresh FDA review

  Oct. 22, 2026

• GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

  Oct. 21, 2026

• Disc’s once-spurned rare disease drug to get a second chance at approval

  Oct. 19, 2026

• This week in charts: Moderna’s massive stock run

  Oct. 16, 2026

• Next-gen RNAi drugmaker City prices $200M IPO

  Oct. 16, 2026

• BioNTech mRNA cancer immunotherapy misses first objective in key study

  Oct. 13, 2026

• First Tracks climbs on ‘impressive’ celiac study data

  Oct. 12, 2026

• HHS launches new plan to strengthen vaccine injury research, reporting

  Oct. 8, 2026

• ArriVent collapses on disappointing lung cancer data

  Oct. 6, 2026

• Pfizer’s eczema drug clears skin in mid-stage trial

  Oct. 1, 2026

• FDA starts review of Roche’s multiple sclerosis pill

  Sept. 30, 2026

• Lisata deal propels Marea’s drug pipeline to Wall Street

  Sept. 17, 2026

• Novartis to pay $125M for blood-brain barrier crossing platform

  Sept. 16, 2026

• AstraZeneca’s newly approved pill fails frontline breast cancer study

  Sept. 14, 2026

• FDA places partial hold on Biohaven’s epilepsy drug

  Sept. 10, 2026

• Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

  Sept. 8, 2026

• GSK wagers up to $1.3B on a different kind of cancer drug

  Sept. 3, 2026

• Novartis says MS pill succeeds in two large studies

  Sept. 1, 2026

• FDA OKs Takeda, Protagonist drug for rare blood cancer

  Aug. 31, 2026

• New data could widen use of AstraZeneca, Amgen immune disease drug

  Aug. 27, 2026

• Spyre tumbles as immune drug misses mark in rheumatoid arthritis

  Aug. 26, 2026

• Will a ‘reset’ reignite investment in women’s health startups?

  Aug. 25, 2026

• Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

  Aug. 24, 2026

• Cancer vaccine win restores Wall Street’s faith in Moderna

  Aug. 20, 2026

• Argenx jumps on Phase 3 data for blockbuster Vyvgart

  Aug. 17, 2026

• Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

  Aug. 11, 2026

• Trump signs order seeking to upend childhood vaccine schedule

  Aug. 11, 2026

• FDA approves Moderna’s mRNA flu vaccine

  Aug. 6, 2026

• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

  Aug. 5, 2026

• BioNTech taps Sobi executive Oelkers as its next CEO

  Aug. 3, 2026

• AbCellera, Vertex partner on next-gen T-cell engagers

  July 29, 2026

• GSK prepares for patent cliff with $2.5B cost-cutting plan

  July 28, 2026

• Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

  July 27, 2026

• Jasper gets a lifeline in merger with immune drugmaker Kira

  July 17, 2026

• Celcuity gains FDA approval for closely watched breast cancer drug

  July 15, 2026

• Draig bags another $65M to speed testing of brain drugs

  July 14, 2026

• GSK, Hansoh ADC extends survival in lung cancer study

  July 10, 2026

• Oberland pours up to $400M into MeiraGTx eye gene therapies

  July 7, 2026

• Vera Therapeutics wins FDA nod for closely watched kidney disease drug

  July 7, 2026

• Novartis to acquire ADC developer in a deal worth up to $1.5B

  July 6, 2026

• Viridian may have edge over Amgen in eye drug showdown, analysts argue

  June 30, 2026

• Ionis, with new FDA nod, hits a ‘commercial inflection point’

  June 24, 2026

• Investors pour $115M into RQ Bio in search of a preventive flu drug

  June 24, 2026

• Pfizer drug acquired in Seagen deal disappoints in lung cancer study

  June 23, 2026

• Moderna flu vaccine wins unanimous support from FDA panel

  June 18, 2026

• FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

  June 16, 2026

• J&J multiple myeloma drug gains edge in earlier stage disease

  June 15, 2026

• Ethyreal starts up with $101M and takes aim at a pair of immune diseases

  June 10, 2026

• Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

  June 9, 2026

• An ADC specialist sinks on safety concerns for blood cancer drug

  June 4, 2026

• Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

  June 2, 2026

• ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

  June 2, 2026

• At ASCO, Merck makes case for a ‘cornerstone’ cancer drug

  May 29, 2026

• FDA delays decision on AstraZeneca breast cancer pill

  May 27, 2026

• Lilly dives into vaccine research with 3 biotech buyouts

  May 26, 2026

• Lilly snaps up Engage to advance non-viral genetic medicines

  May 20, 2026

• BioMarin drug acquired in buyout misses goal in rare disease study

  May 19, 2026

• Create Medicines raises $122M to bolster in vivo CAR-T therapies

  May 14, 2026

• Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

  May 12, 2026

• GSK cuts deal with Sino to broaden reach of hepatitis B drug

  May 11, 2026

• Sarepta tumbles as its gene therapy sales decline further

  May 7, 2026

• Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

  May 6, 2026

• Viridian data lift prospects for thyroid eye disease drug

  May 5, 2026

• Celcuity strengthens case for ASCO-spotlighted breast cancer drug

  May 4, 2026

• Moderna sees revenue bump from international COVID vaccine sales

  May 1, 2026

• UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

  April 30, 2026

• Coultreon banks $125M to support testing of former Galapagos immune drug

  April 28, 2026

• Oruka surges as long-acting psoriasis drug shows early promise

  April 27, 2026

• Sanofi MS drug rejected in US gets an endorsement in Europe

  April 24, 2026

• Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director

  April 16, 2026

• Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

  April 15, 2026

• Travere wins long-awaited approval for kidney disease drug

  April 14, 2026

• Spyre drug for inflammatory bowel disease shows promise in early study

  April 13, 2026

• Invivyd reveals plans to test an antibody drug against measles

  April 9, 2026

• Sidewinder secures $137M to advance ‘precision’ ADCs

  April 8, 2026

• Under-the-skin Tepezza comparable to infused version in key study, Amgen says

  April 6, 2026

• Pfizer, BioNTech to pause COVID vaccine study due to low enrollment

  April 1, 2026

• A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma

  April 1, 2026

• Viridian tumbles on positive data for key eye drug prospect

  March 31, 2026

• Sanofi eczema drug weighed down by mixed results, safety concerns

  March 30, 2026

• Maze tumbles despite positive data for kidney disease drug

  March 25, 2026

• Immutrin raises $87M to advance drug for progressive heart disease

  March 24, 2026

• Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

  March 23, 2026

• Federal court blocks RFK Jr.’s moves to upend US vaccine policy

  March 17, 2026

• CytomX surges on positive data for ‘masked’ ADC in colorectal cancer

  March 16, 2026

• GSK’s RSV vaccine wins broader FDA clearance

  March 13, 2026

• Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial

  March 11, 2026

• BioNTech founders to step down and helm new mRNA startup

  March 10, 2026

• Ipsen to withdraw cancer drug acquired in buyout due to safety concerns

  March 9, 2026

• Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results

  March 6, 2026

• Moderna to pay up to $2.25B to end mRNA vaccine patent fight

  March 4, 2026

• Kyowa Kirin abandons touted eczema drug following safety review

  March 3, 2026

• Ascendis wins FDA approval of dwarfism drug

  March 2, 2026

• Moderna’s combination flu, COVID shot wins over European drug regulators

  Feb. 27, 2026

• 15 states sue HHS over changes to childhood vaccine schedule

  Feb. 25, 2026

• Vir climbs on Astellas deal, study results for ‘masked’ T cell engager

  Feb. 24, 2026

• FDA reverses course on Moderna’s flu vaccine

  Feb. 18, 2026

• FDA removes box warnings for 6 menopausal therapies

  Feb. 13, 2026

• Moderna shares jump as company affirms growth outlook

  Feb. 13, 2026

• Seres to lay off staff, pause top program in latest reboot

  Feb. 12, 2026

• FDA refuses to review Moderna’s mRNA flu vaccine

  Feb. 11, 2026

• Hengrui, Kailera tout positive results for dual-acting obesity pill

  Feb. 9, 2026

• Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials

  Feb. 2, 2026

• Sanofi expects vaccine sales growth to dip amid ‘challenging environment’

  Jan. 29, 2026

• Lilly bets on Seamless, delving further into genetic medicine for hearing loss

  Jan. 28, 2026

• FDA lifts hold on an Intellia CRISPR drug trial

  Jan. 27, 2026

• Bristol Myers buys into Janux’s ‘masked’ T cell engagers

  Jan. 22, 2026

• Valneva to withdraw Chikungunya vaccine from US amid safety woes

  Jan. 20, 2026

• CDC, following Trump’s orders, weakens US stance on childhood vaccinations

  Jan. 6, 2026

• Moderna, searching for a rebound, to seek approval of mRNA flu shot

  Jan. 5, 2026

• Patient deaths put Merck, Daiichi’s ADC trial on partial hold

  Dec. 19, 2025

• Moderna gets funding for H5 pandemic influenza vaccine

  Dec. 18, 2025

• FDA clears GSK’s twice-yearly asthma drug

  Dec. 17, 2025

• Enhertu combo cleared for use in frontline breast cancer

  Dec. 16, 2025

• RFK Jr.’s hand-picked panel questions childhood vaccine schedule

  Dec. 5, 2025

• ‘Discredited’ CDC panel weakens endorsement for newborns’ hepatitis B shot

  Dec. 4, 2025

• Regeneron inks gene editing deal with startup Tessera

  Dec. 1, 2025

• Otsuka gains approval for first-of-its-kind treatment against rare kidney disease

  Nov. 26, 2025

• Kelun, Merck tout ADC as potential first-line treatment in lung cancer

  Nov. 25, 2025

• Biogen strikes deal with Versant-backed biotech to expand immune portfolio

  Nov. 24, 2025

• Moderna secures $1.5B lifeline as it looks to break even in 2028

  Nov. 20, 2025

• RNAi biotech Arrowhead wins first FDA approval

  Nov. 18, 2025

• Solve lines up $120M to push ADCs into further testing

  Nov. 17, 2025

• Novartis, with study success, to seek approval of new kind of malaria drug

  Nov. 12, 2025

• FDA to remove safety warnings on hormonal menopause therapy

  Nov. 10, 2025

• Moderna leans on cost cuts, pipeline as vaccine sales dip

  Nov. 6, 2025

• Blackstone pays Merck $700M to buy into ADC drug royalties

  Nov. 4, 2025

• Neok Bio launches with $75M to make dual-targeting ADCs

  Nov. 4, 2025

• FDA places formal hold on two Intellia CRISPR trials

  Oct. 30, 2025

• Bayer receives FDA approval for non-hormonal menopause therapy

  Oct. 27, 2025

• Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales

  Oct. 24, 2025

• Moderna says CMV vaccine once seen as future blockbuster fails key study

  Oct. 22, 2025

• Sanofi drug acquired in buyout succeeds in rare disease trial

  Oct. 22, 2025

• AstraZeneca, Daiichi’s Datroway excels in hard-to-treat breast cancer

  Oct. 20, 2025

• Novo wagers up to $2.1B on Omeros’ rare disease drug

  Oct. 15, 2025

• BioCryst goes ‘all in’ on rare swelling disease with Astria deal

  Oct. 14, 2025

• Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

  Oct. 8, 2025

• AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer

  Oct. 6, 2025

• Takeda, in reversal, abandons cell therapy research

  Oct. 1, 2025

• Genmab to acquire closely watched cancer drug in $8B Merus buyout

  Sept. 29, 2025

• CDC panel, recast by RFK Jr., softens COVID vaccine recommendations

  Sept. 19, 2025

• CDC advisers postpone vote to delay some newborns’ hepatitis B shot

  Sept. 19, 2025

• Fired CDC director says RFK Jr. aims to change childhood vaccine schedule

  Sept. 17, 2025

• A key CDC panel meets today to discuss vaccines. Here’s what to know.

  Sept. 15, 2025

• Novartis to gain heart drug in $1.4B deal for Tourmaline Bio

  Sept. 9, 2025

• Pfizer, BioNTech showcase new data supporting COVID booster

  Sept. 8, 2025

• At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

  Sept. 4, 2025

• CDC panel to discuss COVID, hepatitis B shots in meeting next month

  Aug. 28, 2025

• FDA approves updated COVID boosters, but narrows use

  Aug. 27, 2025

• Lilly says breast cancer drug extended survival in study

  Aug. 27, 2025

• FDA suspends license for Valneva’s chikungunya shot

  Aug. 25, 2025

• CSL to separate vaccine business, cut jobs

  Aug. 19, 2025

• Kennedy’s mRNA cuts could set US science back, experts warn

  Aug. 18, 2025

• HHS revives defunct task force on childhood vaccine safety

  Aug. 15, 2025

• PureTech launches new biotech built around lung disease drug

  Aug. 12, 2025

• FDA lifts pause on Valneva’s chikungunya shot, but adds new limits

  Aug. 7, 2025

• HHS abandons mRNA vaccine research

  Aug. 6, 2025

• Gates Foundation pledges $2.5B to women’s health research

  Aug. 4, 2025

• Experts ousted from CDC panel warn of damage to US vaccine policy

  July 31, 2025

• Moderna to lay off 10% of workforce in ‘difficult but necessary step’

  July 31, 2025

• Bavarian Nordic agrees to $3B take-private deal

  July 29, 2025

• Celcuity shares triple on late-stage results for breast cancer therapy

  July 28, 2025

• FDA delays approval decision for Bayer menopause therapy

  July 25, 2025

• RFK Jr. adopts CDC panel recommendation to remove thimerosal from flu shots

  July 23, 2025

• Sanofi to acquire vaccine biotech in billion-dollar deal

  July 22, 2025

• FDA panel elevates concerns over antidepressant use during pregnancy

  July 22, 2025

• Panel urges FDA to remove warnings on hormonal menopause therapy

  July 18, 2025

• Moderna’s latest approval again reveals FDA rift over COVID vaccines

  July 16, 2025

• FDA rejects Ultragenyx gene therapy over manufacturing concerns

  July 14, 2025

• Moderna COVID vaccine gets full approval for children

  July 10, 2025

• Novartis gets approval of first malaria medicine for newborns

  July 8, 2025

• Medical groups, pregnant doctor sue RFK Jr. over vaccine changes

  July 7, 2025

• Apogee touts positive data for atopic dermatitis drug

  July 7, 2025

• CDC panel, newly remade by RFK Jr., questions vaccine evidence

  June 25, 2025

• Cassidy challenges RFK Jr. with call for delay to CDC vaccine meeting

  June 24, 2025

• Cidara stock soars as antiviral drug succeeds in flu study

  June 23, 2025

• FDA approves twice-yearly shot of Gilead drug for HIV prevention

  June 18, 2025

• Sage, following setbacks, to sell to Supernus for $561M

  June 16, 2025

• Moderna wins FDA OK to widen use of RSV vaccine

  June 13, 2025

• Vaccine makers face fresh uncertainty after firing of CDC panel

  June 10, 2025

• Merck antibody drug for RSV approved by FDA

  June 9, 2025

• Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

  June 4, 2025

• Bayer drug could ease side effects of common breast cancer treatment, detailed data show

  June 3, 2025

• Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

  June 2, 2025

• FDA clears Moderna’s new COVID vaccine, but with limits

  May 31, 2025

• Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer

  May 31, 2025

• HHS terminates Moderna contract to develop bird flu vaccine

  May 29, 2025

• FDA sets COVID vaccine formula as RFK Jr. narrows guidance for shots

  May 27, 2025

• FDA panel recommends keeping COVID shots targeted to same strain as last year

  May 22, 2025

• Reproductive health startup raises $65M for infertility drugs

  May 21, 2025

• Moderna pulls application for combo COVID, flu shot

  May 21, 2025

• FDA sets stricter approval standards for COVID vaccines

  May 20, 2025

• Novavax’s COVID vaccine gets FDA approval, but with limits

  May 19, 2025

• Women’s health faces growing headwinds, despite jump in venture investment

  May 13, 2025

• FDA follows EMA in limiting use of Valneva shot

  May 12, 2025

• FDA set to meet this month on COVID vaccines

  May 7, 2025

• AI specialist Recursion trims pipeline in latest shakeup

  May 5, 2025

• Moderna combination flu, COVID shot delayed amid FDA scrutiny

  May 1, 2025

• Novavax says vaccine application still ‘approvable,’ despite FDA delay

  April 28, 2025

• Gilead leans on HIV drugs as oncology sales slow

  April 25, 2025

• CDC panel backs broader use of RSV shots

  April 17, 2025

• CDC panel mulls changes to COVID shot recommendations

  April 16, 2025

• Rallybio discontinues lead drug for rare maternal disorder

  April 8, 2025

• FDA misses approval deadline for Novavax’s COVID-19 vaccine

  April 3, 2025

• FDA official’s ouster sends shares of vaccine makers sliding

  March 31, 2025

• FDA approves first-of-its-kind antibiotic from GSK

  March 26, 2025

• Tempero Bio gets $70M to advance substance abuse treatment

  March 24, 2025

• Delayed CDC meeting on vaccines is rescheduled to April

  March 21, 2025

• Taiho buys Swiss biotech and its ADC tech for $400M

  March 17, 2025

• FDA sets flu shot recommendations without input of outside advisers

  March 14, 2025

• Merck opens $1B vaccine plant in North Carolina

  March 11, 2025

• FDA meeting on flu vaccine composition is canceled

  Feb. 27, 2025

• Mirum drug for rare genetic disease gains FDA approval

  Feb. 24, 2025

• CDC vaccine meeting, set to be first since RFK Jr. sworn in, is postponed

  Feb. 20, 2025

• In FDA job cuts, experts see threat of far-reaching impact

  Feb. 20, 2025

• GSK’s 5-in-1 meningococcal shot wins FDA approval

  Feb. 18, 2025

• RFK Jr. confirmed by Senate as health secretary

  Feb. 13, 2025

• AbbVie, Pfizer gain FDA OK for novel antibiotic

  Feb. 10, 2025

• Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

  Feb. 6, 2025

• GSK, Pfizer sales of RSV shots slow as vaccination rates ebb

  Feb. 5, 2025

• RFK Jr. secured support of key Republican with vaccine pledges

  Feb. 4, 2025

• RFK Jr. clears key hurdle on path to become HHS secretary

  Feb. 4, 2025

• RFK Jr. signals he’ll back Trump abortion policies, despite prior stance

  Jan. 29, 2025

• Democrats clash with RFK Jr. over vaccine views at heated Senate hearing

  Jan. 29, 2025

• Sage rebuffs Biogen bid to take it over

  Jan. 27, 2025

• FDA clears monthly dosing of Alzheimer’s drug Leqembi

  Jan. 27, 2025

• Moderna gets $590M from US government for bird flu vaccine

  Jan. 21, 2025

• JPM25: Deals, Summit’s bravado and gene therapy headwinds

  Jan. 13, 2025

• Moderna shares tumble on slashed sales guidance

  Jan. 13, 2025

• 5 questions facing pharma in 2025

  Jan. 9, 2025

• Bayer says menopause drug succeeds in breast cancer study

  Jan. 9, 2025

• FDA adds warning to RSV shots from GSK, Pfizer

  Jan. 8, 2025

• Vertex, startup Orna to partner on gene editing research

  Jan. 7, 2025

• Novartis shutters MorphoSys sites, lays off staff

  Dec. 19, 2024

• Merck targets 2025 RSV season with antibody now under FDA review

  Dec. 17, 2024

• FDA panel seeks more data on RSV vaccine safety in infants

  Dec. 13, 2024

• ‘Research that’s desperately needed’: White House conference spotlights women’s health

  Dec. 12, 2024

• Endometriosis drug research, long underfunded, confronts familiar problems in women’s health

  Dec. 9, 2024

• Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

  Dec. 3, 2024

• Applied’s rare disease drug rejected by FDA

  Dec. 2, 2024

• Syndax secures FDA OK for new kind of leukemia drug

  Nov. 18, 2024

• Surviving in biotech’s new normal: 5 tips from industry VCs and CEOs

  Nov. 15, 2024

• FDA lifts pause on Novavax flu vaccine trials

  Nov. 11, 2024

• Kalaris to go public via reverse merger with AlloVir

  Nov. 8, 2024

• Neurogene secures $200M ahead of anticipated study readout

  Nov. 4, 2024

• GSK vaccine sales sink on lower demand for RSV, shingles shots

  Oct. 30, 2024

• Pfizer sales of RSV vaccine ebb, but company gains market share

  Oct. 29, 2024

• Sanofi earnings boosted by Beyfortus, earlier vaccine sales

  Oct. 25, 2024

• Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines

  Oct. 24, 2024

• Pfizer’s RSV vaccine cleared by FDA for use in some younger adults

  Oct. 23, 2024

• Sanofi moves ahead with CD&R deal for stake in consumer business

  Oct. 21, 2024

• Merck antibody reduces RSV-related disease, hospitalizations in trial

  Oct. 18, 2024

• Sage to cut one-third of workforce, streamline drug pipeline

  Oct. 17, 2024

• FDA puts Novavax flu vaccine trials on hold

  Oct. 16, 2024

• Forbion follows string of startup exits with $2.2B fundraise

  Oct. 15, 2024

• GSK says antibody drug succeeds in testing for chronic nasal condition

  Oct. 14, 2024

• Purespring raises $105M to advance gene therapy for kidney disease

  Oct. 9, 2024

• GSK says RSV vaccine protects against disease over three seasons

  Oct. 8, 2024

• GSK’s ViiV to expand supply of HIV drug in Africa

  Oct. 7, 2024

• Editas trades Vertex fees for upfront cash in DRI deal

  Oct. 4, 2024

• Gilead agrees to license new HIV drug in low-income countries

  Oct. 2, 2024

• Aktis raises $175M to fuel radiopharma drug development

  Sept. 30, 2024

• Bluebird to lay off another 25% of workforce in latest restructuring

  Sept. 24, 2024

• Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines

  Sept. 23, 2024

• Roche’s Xofluza reduces flu transmission in Phase 3 study

  Sept. 19, 2024

• Sanofi readies to meet US demand for RSV antibody

  Sept. 16, 2024

• Moderna, trailing rivals, checks its RSV shot expectations

  Sept. 13, 2024

• F2G raises $100M to bring antifungal drug back to FDA

  Sept. 12, 2024

• Bain closes $3B biotech fund amid flurry of startup buyouts

  Sept. 10, 2024

• BioMarin, having retrenched, outlines plans for growth

  Sept. 4, 2024

• Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares

  Sept. 3, 2024

• BioMarin to lay off over 200 employees

  Aug. 29, 2024

• Bayer partners with RNA drugmaker to develop new cancer therapies

  Aug. 28, 2024

• Pfizer launches DTC service for migraine, COVID drugs

  Aug. 27, 2024

• Tome Biosciences to lay off over 100 employees

  Aug. 26, 2024

• Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot

  Aug. 16, 2024

• Pfizer builds case for RSV shot with data from immunocompromised adults

  Aug. 12, 2024

• Zepbound shortages ease, but Lilly cautions pharmacy availability may remain ‘choppy’

  Aug. 8, 2024

• Biotech entrepreneur Arie Belldegrun launches new ‘science-first’ credit firm

  Aug. 6, 2024

• Biotech Red Queen launches with $55M to build versatile antivirals

  Aug. 6, 2024

• UniQure restructuring to claim 300 jobs

  Aug. 1, 2024

• Moderna shares fall amid lower sales outlook for RSV, COVID shots

  Aug. 1, 2024

• J&J seeks expanded approval for antidepressant Spravato

  July 22, 2024

• NGM, now private, raises $122M for redrawn research plans

  July 17, 2024

• HilleVax’s norovirus vaccine ineffective in large trial of infants

  July 8, 2024

• Moderna gets US funding for bird flu vaccine development

  July 2, 2024

• Eli Lilly inks another radiopharma deal, gaining option to buy startup

  July 1, 2024

• Merck’s pneumococcal vaccine gets CDC panel backing

  June 28, 2024

• RSV vaccine makers’ shares fall as CDC adjusts shot guidance

  June 27, 2024

• Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help?

  June 26, 2024

• Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot

  June 18, 2024

• Abortion pill ruling offers measure of relief for FDA, biotech

  June 17, 2024

• Supreme Court preserves access to abortion pill in unanimous ruling

  June 13, 2024

• Flagship taps startup to hunt for obesity drugs that might interest Pfizer

  June 12, 2024

• Moderna says combination flu, COVID shot succeeds in study

  June 10, 2024

• GSK acquires oligonucleotide drug startup Elsie

  June 6, 2024

• FDA advisers back updating COVID shots to target JN.1 virus family

  June 6, 2024

• Structure pill leads to competitive weight loss in obesity study

  June 3, 2024

• Moderna wins FDA approval for RSV vaccine

  May 31, 2024

• A biotech working on a new approach to IVF raises $33M in fresh funding

  May 29, 2024

• Agios cashes in on cancer drug again with $905M Royalty Pharma deal

  May 28, 2024

• Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

  May 23, 2024

• Lilly partners with Aktis, deepening radiopharma investment

  May 21, 2024

• Detailed trial data show Bayer drug alleviates menopause symptoms

  May 16, 2024

• Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

  May 15, 2024

• Bayer details layoffs as company shake-up continues

  May 14, 2024

• FDA delays decision on Moderna RSV vaccine

  May 10, 2024

• AstraZeneca withdraws COVID-19 vaccine, citing declining demand

  May 8, 2024

• Novartis to buy Mariana Oncology in radiopharmaceutical expansion

  May 2, 2024

• GSK raises forecasts on strong vaccine, HIV drug sales

  May 1, 2024

• Biogen sees ‘encouraging’ trends for postpartum depression drug

  April 24, 2024

• Former Bristol Myers CEO tapped as Novartis’ next board chair

  April 23, 2024

• Lilly to buy injectable drug plant in manufacturing ramp-up

  April 22, 2024

• Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

  April 22, 2024

• Regeneron commits $500M to new venture capital fund

  April 15, 2024

• Century buys a startup, raises funding in cell therapy expansion

  April 11, 2024

• J&J, Rallybio partner on drug development for rare fetal condition

  April 10, 2024

• New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way.

  April 10, 2024

• Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59

  April 9, 2024

• Boehringer Ingelheim to lay off staff amid biosimilar challenges

  April 5, 2024

• Roivant reveals positive immune drug data, share buyback plans

  April 2, 2024

• Vertex moves kidney disease drug into late-stage testing

  April 1, 2024

• Moderna gets Blackstone backing for flu vaccine R&D

  March 27, 2024

• Supreme Court weighs abortion opponents’ standing in mifepristone case

  March 26, 2024

• AbbVie to buy immune drug developer Landos

  March 25, 2024

• NextCure to lay off 37% of staff, dial back research plans

  March 21, 2024

• With new data, Bayer readies rival to Astellas menopause drug

  March 19, 2024

• Bluebird, short on cash, takes on $175M in debt financing

  March 18, 2024

• Merck reveals plans to develop newer HPV shots

  March 13, 2024

• Boehringer, Sosei Heptares team up in schizophrenia drug deal

  March 11, 2024

• Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work

  March 6, 2024

• CVS, Walgreens to start selling abortion pill in some states

  March 4, 2024

• CDC panel mulls changes to RSV vaccine recommendation

  March 1, 2024

• Women’s health company Obseva to wind down, lay off staff

  Feb. 28, 2024

• Denali, fresh off study setback, gets $500M lift

  Feb. 27, 2024

• GSK drug meets goal in late-stage gonorrhea study

  Feb. 26, 2024

• Biden administration pledges $100M toward women’s health research

  Feb. 22, 2024

• Vir, in midst of restructuring, loses its chief medical officer

  Feb. 21, 2024

• FDA puts hold on Rapt trials of drug for eczema, asthma

  Feb. 20, 2024

• ALS drug from Denali, Sanofi falls short in mid-stage study

  Feb. 16, 2024

• LianBio to shut down, return cash to investors

  Feb. 14, 2024

• Alys launches with $100M and a pipeline of skin disease drugs

  Feb. 12, 2024

• BridgeBio sells partial rights to dwarfism drug for $100M

  Feb. 7, 2024

• Valneva sells regulatory ‘fast pass’ for $103M

  Feb. 5, 2024

• Sanofi appoints Nestlé executive as new finance chief

  Feb. 1, 2024

• GSK sales of RSV vaccine stay strong, beating forecast

  Jan. 31, 2024

• At FDA meeting, experts wrestle with hurdles to developing preterm birth drugs

  Jan. 25, 2024

• Coherus sells Lucentis biosimilar to Sandoz for $170M

  Jan. 22, 2024

• Ikena Oncology to lay off 35% of staff

  Jan. 19, 2024

• Comanche Biopharma raises $75M to fund preeclampsia drug testing

  Jan. 17, 2024

• Women’s health companies, battling under-investment in research, see growing opportunity

  Jan. 16, 2024

• JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform

  Jan. 9, 2024

• JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job

  Jan. 8, 2024

• Year of biotech layoffs leaves industry looking for spark

  Jan. 8, 2024

• Novartis deepens ties with Voyager via $100M gene therapy deal

  Jan. 2, 2024

• 10 clinical trials to watch in the first half of 2024

  Jan. 2, 2024

• Merck gets FDA decision date for new pneumococcal vaccine

  Dec. 19, 2023

• Foundation behind Novo Nordisk to invest $260M in vaccine R&D

  Dec. 18, 2023

• Vir to lay off staff, cut costs amid setbacks building on COVID success

  Dec. 14, 2023

• Supreme Court to rule on abortion pill access

  Dec. 13, 2023

• AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B

  Dec. 12, 2023

• Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs

  Dec. 8, 2023

• Fujifilm to invest $200M in cell therapy production

  Dec. 6, 2023

• Pfizer, after delay, completes enrollment in Lyme vaccine trial

  Dec. 5, 2023

• Concentra, on the hunt for deals, bids for LianBio

  Dec. 1, 2023

• Gilead to lay off staff at cell therapy unit Kite

  Nov. 29, 2023

• Novo to expand French plant in GLP-1 production push

  Nov. 27, 2023

• Merck to buy private biotech Caraway in neuroscience deal

  Nov. 21, 2023

• Homology enters reverse merger with Q32 Bio

  Nov. 16, 2023

• Alkermes separates cancer drug business as new company Mural

  Nov. 15, 2023

• Forbion-backed biotech raises $138M to develop ALS drug

  Nov. 14, 2023

• Valneva’s chikungunya vaccine approved by FDA

  Nov. 10, 2023

• Takeda secures FDA approval for colon cancer drug

  Nov. 9, 2023

• Flagship expands into Asia-Pacific with new Singapore hub

  Nov. 7, 2023

• Ventyx revises TYK2 drug plans after lackluster study data

  Nov. 7, 2023

• Moderna adjusts to changing outlook for COVID vaccine demand

  Nov. 3, 2023

• Sangamo to cut jobs again with planned business overhaul

  Nov. 2, 2023

• Pfizer RSV vaccine gets off to fast start on market

  Oct. 31, 2023

• Sanofi invests in MeiraGTx and its gene-regulating technology

  Oct. 30, 2023

• Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

  Oct. 26, 2023

• Supply shortage hits infant RSV antibody Beyfortus

  Oct. 25, 2023

• OrbiMed raises $4.3B in new funds for startup investing

  Oct. 24, 2023

• Pfizer wins FDA approval of new meningococcal vaccine

  Oct. 23, 2023

• Concentra makes bid for struggling biotech Rain

  Oct. 16, 2023

• ‘Project NextGen’ picks new mRNA, intranasal COVID vaccines for funding

  Oct. 13, 2023

• Research group says FDA found no misconduct in Pfizer Lyme vaccine trial it helped run

  Oct. 12, 2023

• Bayer opens California plant to make cell therapies

  Oct. 10, 2023

• GSK partners with Chinese pharma to expand Shingrix sales

  Oct. 9, 2023

• Moderna claims positive results in early study for combo COVID, flu shot

  Oct. 4, 2023

• Lilly eczema drug turned back by FDA over manufacturing

  Oct. 2, 2023

• PTC to lay off more staff following drug setback in Europe

  Sept. 29, 2023

• Gritstone wins ‘Project NextGen’ funding to run head-to-head COVID vaccine study

  Sept. 28, 2023

• Latest trial win supports expanded use of Bristol Myers’ Opdivo in lung cancer

  Sept. 22, 2023

• Roche’s Genentech bets on radiopharmaceuticals in partnership with PeptiDream

  Sept. 20, 2023

• Kinnate lays off 70% of staff, reorganizes pipeline

  Sept. 19, 2023

• New RSV vaccines can be powerful tools, but rollout poses test

  Sept. 18, 2023

• CDC endorses new COVID boosters as focus turns to rollout

  Sept. 13, 2023

• FDA approves updated COVID boosters from Pfizer, Moderna

  Sept. 11, 2023

• Novartis stops work on gene therapy acquired in Gyroscope deal

  Sept. 11, 2023

• AstraZeneca, seeking new drug targets, taps a genomics biotech and its AI technology

  Sept. 8, 2023

• Startup Mariana raises $175M for radiopharmaceutical drug research

  Sept. 7, 2023

• Moderna says updated COVID shot likely to protect against worrisome variant

  Sept. 6, 2023

• Nestle gives up on peanut allergy treatment after sluggish sales

  Sept. 5, 2023

• FibroGen’s Duchenne drug fails second trial in latest study setback

  Aug. 30, 2023

• Merck kicks off Phase 3 tests for PCSK9 cholesterol pill

  Aug. 25, 2023

• Agenus to lay off 25% of staff, trim pipeline in cancer drug push

  Aug. 23, 2023

• FDA approves Pfizer’s RSV vaccine for use in pregnancy

  Aug. 21, 2023

• Genesis raises $200 million for AI drug discovery research

  Aug. 21, 2023

• Appeals court rules to limit abortion pill access

  Aug. 16, 2023

• FDA delays decision on Valneva’s chikungunya vaccine

  Aug. 14, 2023

• Family of Henrietta Lacks sues Ultragenyx over use of HeLa cell line

  Aug. 11, 2023

• Astellas to expand presence in Massachusetts with new research hub

  Aug. 10, 2023

• Ikena acquires cancer startup Pionyr after Gilead passes on buyout

  Aug. 7, 2023

• RSV antibody from Sanofi, AstraZeneca backed by CDC for use in infants

  Aug. 4, 2023

• Moderna looks to new COVID booster, RSV shot to curb falling sales

  Aug. 3, 2023

• Karyopharm cuts staff amid push to broaden use of blood cancer drug

  Aug. 2, 2023

• FDA declines to review Biohaven’s latest drug in setback to pipeline

  July 27, 2023

• GSK confident in RSV vaccine launch, but sets expectations for ‘steady build’

  July 27, 2023

• FibroGen CEO resigns amid latest round of layoffs

  July 25, 2023

• Bavarian Nordic to scrap RSV vaccine after study setback

  July 24, 2023

• EMA backs Pfizer’s RSV vaccine for use during pregnancy

  July 21, 2023

• Vir, struggling to build on COVID success, says flu antibody fails key study

  July 20, 2023

• Amarin, Fibrogen lay off staff as biotech cost cutting continues

  July 19, 2023

• A cancer biotech’s collapse gives Neurogene a path to Wall Street

  July 18, 2023

• FDA approves new RSV drug to protect infants, toddlers

  July 17, 2023

• Novartis buys a preclinical biotech and its RNA drug technology

  July 17, 2023

• RNA editing specialist Korro to go public via reverse merger

  July 14, 2023

• First nonprescription birth control pill approved by FDA

  July 13, 2023

• Takeda withdraws FDA approval application for dengue vaccine

  July 11, 2023

• Septerna raises $150M to fuel GPCR drug research

  July 11, 2023

• Astellas buys rights to 4D Molecular’s technology in latest gene therapy deal

  July 10, 2023

• Brii buys further into VBI therapy, expanding hepatitis B partnership

  July 6, 2023

• Ipsen gains FDA panel backing for bone drug acquired in $1.3B buyout

  June 29, 2023

• Pfizer’s hemophilia B gene therapy inches closer to regulatory approval

  June 27, 2023

• 5 FDA decisions to watch in the third quarter

  June 26, 2023

• Bavarian Nordic says chikungunya vaccine succeeds in late-stage study

  June 20, 2023

• FDA advisers endorse updating COVID shots to match circulating virus strain

  June 16, 2023

• Acadia gives once-rejected Prader-Willi drug a second chance

  June 14, 2023

• Ferring, with manufacturing update, takes a step towards first gene therapy sales

  June 13, 2023

• Novo Nordisk to invest over $2B in drug ingredient production

  June 12, 2023

• FDA advisers back RSV antibody drug for use in infants

  June 9, 2023

• FDA staff appear supportive of RSV drug from AstraZeneca, Sanofi

  June 6, 2023

• Pfizer says antibiotic is effective against tough-to-treat infections

  June 2, 2023

• AstraZeneca abandons experimental bowel disease drug

  June 1, 2023

• Pfizer’s RSV vaccine wins FDA approval in older adults

  May 31, 2023

• Biohaven sends latest drug to FDA, despite past trial setback

  May 31, 2023

• Amylyx’s ALS drug could face rejection in Europe

  May 30, 2023

• BenevolentAI CFO resigns as company lays off staff, restructures

  May 25, 2023

• FDA approves new antibiotic for hospital-acquired pneumonia

  May 24, 2023

• FDA approves Krystal gene therapy for rare wound disorder

  May 22, 2023

• Novavax cuts workforce by 25% as COVID vaccine sales fall

  May 9, 2023

• Former Rubius, Laronde CEO Cagnoni to join Incyte

  May 8, 2023

• Convergent raises $90M to develop its radiopharmaceutical for prostate cancer

  May 5, 2023

• Valneva, Pfizer push back timeline for Lyme disease vaccine

  May 4, 2023

• FDA approves first RSV vaccine, clearing GSK’s Arexvy for older adults

  May 3, 2023

• J&J, building on CAR-T success, strikes another cell therapy deal

  May 2, 2023

• FDA clears Pfizer’s pneumococcal vaccine for infants and children

  April 28, 2023

• Novartis plant cleared to produce in-demand cancer drug

  April 24, 2023

• Supreme Court maintains access to abortion pill, blocking restrictions on its use

  April 21, 2023

• Supreme Court delays decision in battle over abortion pill

  April 19, 2023

• FDA favors single dose of updated COVID shots in shift to simplify vaccination

  April 18, 2023

• Vaxcyte strengthens case for experimental pneumococcal vaccine

  April 17, 2023

• Appeals court rules abortion drug can stay on market — but limits access

  April 13, 2023

• Century Therapeutics changes leadership as CEO steps down

  April 12, 2023

• Biotech fears ‘dangerous’ precedent as judge challenges FDA authority

  April 10, 2023

• Federal judge invalidates FDA approval of abortion pill

  April 8, 2023

• AbbVie removes two approvals for blood cancer drug Imbruvica

  April 7, 2023

• In NEJM, full Pfizer data show RSV vaccine’s protection

  April 5, 2023

• BioNTech moves into ADCs with Duality deal

  April 3, 2023

• 5 FDA decisions to watch in the second quarter

  April 3, 2023

• FDA approves Narcan for over-the-counter use

  March 30, 2023

• Novartis taps Bicycle to develop radiopharmaceutical drugs for cancer

  March 28, 2023

• Novo partners with Dewpoint to mine an emerging field for new drugs

  March 22, 2023

• Novo Nordisk follows Lilly in sharply cutting insulin prices

  March 14, 2023

• Sanofi acquires diabetes drug via Provention buyout

  March 13, 2023

• Sandoz, betting on biosimilar sales, to build new production plant

  March 9, 2023

• Controversial drug for preterm birth to be withdrawn, maker says

  March 8, 2023

• FDA decision on preterm birth drug’s withdrawal nears, putting spotlight on patients, agency

  March 6, 2023

• Novartis takes step toward expanding supply of in-demand cancer drug

  March 3, 2023

• GSK’s RSV vaccine wins FDA panel backing, matching Pfizer

  March 2, 2023

• Pfizer’s RSV vaccine gets lukewarm backing of FDA advisers

  March 1, 2023

• Viatris taps new CEO to lead second phase of business revamp

  Feb. 27, 2023

• Moderna shares sink amid COVID forecasts, trial news

  Feb. 23, 2023

• Merck’s COVID-19 treatment falls short in prevention study

  Feb. 21, 2023

• Moderna shares sink on mixed study results for flu vaccine

  Feb. 17, 2023

• New cancer cell therapy biotech emerges, backed by MD Anderson and Replay

  Feb. 14, 2023

• Frequency to cut jobs after clinical trial setback

  Feb. 13, 2023

• Pfizer begins plan to challenge Shingrix with an mRNA vaccine

  Feb. 10, 2023

• Arrowhead confirms J&J’s plan to dial back hepatitis B drug research

  Feb. 7, 2023

• J&J says drug it acquired from Momenta succeeds in study of ultra-rare condition

  Feb. 6, 2023

• COVID-19 vaccine maker Medicago to close down

  Feb. 3, 2023

• FDA to convene advisers on review of RSV vaccines from GSK, Pfizer

  Feb. 1, 2023

• 3 more biotechs announce layoffs as industry cost-cutting continues

  Feb. 1, 2023

• Moderna reports positive RSV vaccine results, pressuring Pfizer, GSK

  Jan. 18, 2023

• Leap Therapeutics to buy Flame Biosciences in all-stock deal

  Jan. 17, 2023

• EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma

  Jan. 13, 2023

• JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor

  Jan. 11, 2023

• Novavax’s Erck to depart after 12 years as CEO

  Jan. 9, 2023

• 5 FDA decisions to watch in the first quarter

  Jan. 9, 2023

• Ensoma buys a startup to advance ‘in vivo’ cell therapy work

  Jan. 6, 2023

• Kenvue, J&J’s consumer health unit, files for an IPO in step toward split

  Jan. 5, 2023

• Prevail, Capsida partner to develop gene therapies for nervous system diseases

  Jan. 4, 2023

• Pfizer says hemophilia B gene therapy controlled bleeding in key study

  Dec. 29, 2022

• Hearing loss biotech Otonomy plans to dissolve

  Dec. 20, 2022

• Ferring wins FDA approval for bladder cancer gene therapy

  Dec. 19, 2022

• Sio Gene Therapies to dissolve after years of setbacks

  Dec. 15, 2022

• Cytokinetics heart drug voted down by FDA panel

  Dec. 14, 2022

• Black Diamond spins out new biotech to develop cancer drugs

  Dec. 13, 2022

• Biotech layoffs claim more jobs at Sensei, Instil, TherapeuticsMD

  Dec. 9, 2022

• Immune drug developer Apogee emerges as first spinout of biotech Paragon

  Dec. 7, 2022

• Verve shares slide after company reveals details on FDA trial hold

  Dec. 6, 2022

• TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout

  Dec. 5, 2022

• J&J’s Duato to replace departing Gorsky as board chair

  Dec. 2, 2022

• Roche study failure gives Alzheimer’s researchers new clues in drug quest

  Dec. 1, 2022

• Sana reshuffles drug pipeline, becoming latest biotech to cut staff

  Nov. 30, 2022

• Spectrum to lay off R&D staff after FDA drug rejection

  Nov. 28, 2022

• Novartis, research group to advance new kind of malaria drug into late-stage test

  Nov. 23, 2022

• Biotech ObsEva sells drug rights to forestall funding crunch

  Nov. 22, 2022

• Replay reveals second gene therapy spinout, debuting new biotech Telaria

  Nov. 21, 2022

• First-of-its-kind Type 1 diabetes drug wins FDA approval

  Nov. 18, 2022

• Pfizer, BioNTech start study testing next COVID-19 vaccine

  Nov. 17, 2022

• Biotechs reveal layoffs, research revamps in third quarter earnings

  Nov. 16, 2022

• Trial failures end latest hope for Roche’s Alzheimer’s drug

  Nov. 14, 2022

• Novavax details trial results for omicron-targeting booster shots

  Nov. 8, 2022

• Viatris to buy two eye drug developers in deals worth up to $750M

  Nov. 7, 2022

• Pfizer, BioNTech data support new Covid booster’s advantage over original vaccine

  Nov. 4, 2022

• Moderna cuts sales forecasts for its COVID-19 vaccine

  Nov. 3, 2022

• Surface Oncology to lay off 20% of staff in restructuring

  Nov. 2, 2022

• Replay launches gene therapy spinout Eudora, putting ‘hub-and-spoke’ plans to work

  Oct. 31, 2022

• GSK shelves filing plans for arthritis drug after trial results

  Oct. 27, 2022

• Astellas takes stake in gene therapy developer Taysha

  Oct. 24, 2022

• ‘I don’t feel safe.’ Abortion bans add new uncertainty to fertility treatment

  Oct. 24, 2022

• Pfizer, BioNTech say updated COVID booster raised omicron antibody levels in trial

  Oct. 13, 2022

• Nimbus partners with Eli Lilly on metabolic disease research

  Oct. 12, 2022

• FDA rejects Supernus’ drug infusion device for Parkinson’s

  Oct. 10, 2022

• BioNTech to build an mRNA hub in Australia

  Oct. 6, 2022

• Nobel Prize in chemistry awarded to biotech founder Bertozzi, two others

  Oct. 5, 2022

• AstraZeneca to acquire gene editing biotech LogicBio

  Oct. 3, 2022

• 5 FDA decisions to watch in the fourth quarter

  Oct. 3, 2022

• BioMarin resubmits its hemophilia gene therapy to the FDA

  Sept. 30, 2022

• J&J’s consumer health spinout to be named Kenvue

  Sept. 28, 2022

• Pfizer, BioNTech seek FDA clearance for updated COVID-19 booster in children

  Sept. 26, 2022

• Pfizer, Sangamo set to resume gene therapy study after safety delay

  Sept. 23, 2022

• J&J opens new research hub near San Francisco

  Sept. 20, 2022

• GenFit, continuing rebuild, buys startup Versantis

  Sept. 19, 2022

• AstraZeneca claims positive results for its “add-on” drug for rare blood disease

  Sept. 16, 2022

• Pfizer brings mRNA flu vaccine into Phase 3 testing

  Sept. 14, 2022

• Bluebird CFO resigns ahead of gene therapy launch

  Sept. 12, 2022

• Backed by Bristol Myers, ArsenalBio raises $220M for its cell therapy research

  Sept. 7, 2022

• CDC backs updated COVID shots from Pfizer, Moderna

  Sept. 2, 2022

• Biotech startup Ocean pivots from IPO to SPAC merger

  Aug. 31, 2022

• FDA clears updated COVID-19 boosters from Pfizer, Moderna

  Aug. 31, 2022

• Pfizer follows GSK with positive Phase 3 results for RSV vaccine

  Aug. 25, 2022

• Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers

  Aug. 25, 2022

• Pfizer’s new pneumococcal vaccine meets study goal in children

  Aug. 12, 2022

• Shifting focus, ProQR to seek partners for stalled eye drugs

  Aug. 11, 2022

• Pfizer, Valneva take next step with Lyme disease shot, starting large trial

  Aug. 9, 2022

• Lilly criticizes Indiana abortion law, indicating it may look elsewhere to hire

  Aug. 8, 2022

• Pfizer buys sickle cell drugmaker Global Blood for $5.4B

  Aug. 8, 2022

• ElevateBio, Boston Children’s launch startup to test new approach to ‘off-the-shelf’ cell therapy

  Aug. 4, 2022

• AbCellera inks another venture partnership, this time with Atlas

  Aug. 3, 2022

• How Belite Bio, a small, under-the-radar drugmaker, emerged as one of biotech’s best performing IPOs

  Aug. 2, 2022

• Ipsen, continuing oncology push, pays a startup $45M for two cancer drugs

  Aug. 1, 2022

• US secures updated COVID boosters in $1.7B deal with Moderna

  July 29, 2022

• Vertex to move non-opioid painkiller into late-stage tests after FDA agreement

  July 22, 2022

• CDC backs Novavax's protein-based vaccine for COVID-19

  July 20, 2022

• Biotech downturn hits another startup as Pact Pharma to lay off nearly 100 employees

  July 19, 2022

• Nestlé expands microbiome drug work with biotech deal

  July 18, 2022

• CytomX lays off staff, joining growing list of biotechs restructuring

  July 14, 2022

• TherapeuticsMD buyout unravels as shareholders balk

  July 13, 2022

• Bain Capital backs new biotech startup developing oral asthma drug

  July 12, 2022

• Moderna founder launches Apriori with $50M to stay ahead of virus variants

  July 11, 2022

• ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug

  July 8, 2022

• Two cancer biotechs merge, raise cash as sector-wide downturn continues

  July 5, 2022

• Pfizer seeks full FDA approval of Paxlovid as questions about its benefits grow

  June 30, 2022

• Bayer, Amgen back ReCode's plan to broaden genetic medicine's reach

  June 29, 2022

• Novartis to invest $250M in tropical disease drug research

  June 22, 2022

• A biotech startup launches with $38M to develop a cystic fibrosis gene therapy

  June 21, 2022

• Boehringer extends cancer dealmaking with right to buy biotech partner

  June 16, 2022

• Forbion raises $500M to back growing biotechs amid industry slump

  June 10, 2022

• Pfizer to invest $120M, add jobs in Paxlovid production push

  June 7, 2022

• Biotech Athersys to lay off 70% of staff in cost-cutting effort

  June 6, 2022